The discussion highlights the challenges in developing biologic medicines, emphasizing their high costs and lengthy production times. While small molecules are relatively inexpensive to manufacture, biologics require complex processes that drive up expenses. The need for computational methods to streamline discovery and production is underscored, aiming to make these critical treatments more accessible.
